CLAIMS

1. An implantable composition comprising an acellular collagen matrix together with poly(lactic-co-glycolic acid) copolymer (PLGA), polyethylene glycol (PEG) 8000 and paclitaxel, wherein:

the PLGA has a molecular weight ranging from about 20,000 g/mol to about 250,000 g/mol;

the PLGA has a lactide/glycolide molar ratio of about 40:60 to about 60:40;

the paclitaxel is present in an amount of 50% by weight or less based on the total weight of the PLGA and PEG 8000; and

the PEG 8000 is present in an amount of between about 5% by weight to about 35% by weight based on the total weight of the PLGA and the paclitaxel.

2. The implantable composition of claim 1, wherein the PLGA, polyethylene glycol 8000, and paclitaxel are embedded in the matrix, coated on the matrix, and is embedded in and coated on the matrix, or covalently linked to the matrix.

3. The implantable composition of claim 2, wherein the paclitaxel is present in an amount of about 25% by weight or less of the total weight of the PLGA and polyethylene glycol 8000 embedded in the matrix, coated on the matrix, or embedded in and coated on the matrix.

4. The implantable composition of claim 1, wherein the poly(lactic-co-glycolic acid) copolymer (PLGA) has a lactide/glycolide molar ratio of about 45:55, about 53:47, about 55:45, or about 50:50.

5. The implantable composition of claim 1, wherein the poly(lactic-co-glycolic acid) copolymer (PLGA) has a molecular weight ranging from about 50,000 g/mol to about 150,000 g/mol.

6. The implantable composition of claim 1, wherein the PLGA has a lactide/glycolide molar ratio of about 50:50.

7. An implantable composition comprising about 25% polyethylene glycol (PEG) 8000, poly(lactic-co-glycolic acid) copolymer (PLGA) having a lactide/glycolide molar ratio of about 50:50, and paclitaxel in an amount of 50% by weight or less based on the total eight of the PLGA and PEG 8000, wherein the PEG 8000, PLGA, and paclitaxel are coated on an acellular collagen matrix.